Drug Profile


Alternative Names: BG 9924; LTβR-Ig; Lymphotoxin-β receptor fusion protein

Latest Information Update: 08 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen Idec; National Institute of Allergy and Infectious Diseases
  • Class Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Lymphotoxin beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome
  • Discontinued Crohn's disease; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 01 Nov 2015 The National Institute of Allergy and Infectious Diseases completes phase II trial in Sjögren's syndrome in USA (NCT01552681)
  • 04 Feb 2011 Phase-II clinical trials in Ulcerative colitis (SC)
  • 21 Oct 2009 Interim efficacy and adverse events data from a phase IIb trial in Rheumatoid arthritis presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top